 |
ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.
The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 2440 Research Blvd., Suite 400, Rockville, MD, 20850.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Contacts
Investors & Media |
Tyler Ehler |
Senior Director, Investor Relations |